Q4 2023 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2024-02-14 · accession 0001727492-24-000002
$296.5M
Reported value
11
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORP | $124.6M | 42.0% | 10,360,945 | Common | SOLE |
| 016259202 | — | ALIMERA SCIENCES INC | $72.7M | 24.5% | 16,835,154 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $24.5M | 8.26% | 1,081,360 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $21.8M | 7.37% | 910,730 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $15.6M | 5.25% | 7,042,413 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $13.9M | 4.68% | 1,317,856 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $9.8M | 3.32% | 441,833 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $7.2M | 2.41% | 1,048,425 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $3.6M | 1.23% | 183,064 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $2.1M | 0.72% | 473,087 | Common | SOLE |
| 75629F109 | RAH | SOCIETAL CDMO INC | $592,264 | 0.20% | 1,689,768 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.